Merck KGaA Appoints New CEO and ChairBy
Belén Garijo, currently Deputy Chief Executive Officer (CEO), CEO Healthcare, and Vice Chair of the Executive Board of Merck KGaA, has been named as the company’s new Chair of the Executive Board and CEO, effective May 1, 2021.
Stefan Oschmann, current Chair of the Executive Board and CEO, Merck KGaA, will leave the company at the end of April 2021, as planned after 10 years on the Executive Board, five of them as Chairman and CEO.
Additionally, Peter Guenter, CEO of Almirall, a Barcelona-based provider of medicines and medical devices, will join the Executive Board of Merck KGaA, effective January 1, 2021, at the latest. He will assume board responsibility for the Healthcare business sector and will be located in Darmstadt, Germany. Guenter has been CEO of Almirall since 2017, and prior to that, held various country, regional, and global management positions at Sanofi since 1995, last as Executive Vice President, Global Diabetes and Cardiovascular.
In addition, Matthias Heinzel, President, Nutrition & Biosciences at DuPont, will join the Executive Board of Merck KGaA, effective April 1, 2021, at the latest. He will assume board responsibility for the Life Science business sector and will be located in Burlington, Massachusetts and Darmstadt, Germany. Mr. Heinzel is currently President Nutrition & Biosciences at DuPont, based in Copenhagen, Denmark, and is a Member of DuPont’s Executive Board. Prior to that, he held various global executive positions at DuPont in the US and Germany since 2003.
Source: Merck KGaA